Mid-Afternoon Market Update: Dow Jumps Over 200 Points; Neuronetics Shares Plunge
Toward the end of trading Tuesday, the Dow traded up 0.64% to 35,059.40 while the NASDAQ rose 0.34% to 14,731.57. The S&P also rose, gaining 0.65% to 4,415.65.
Understanding Arcturus Therapeutics’s Unusual Options Activity
On Tuesday, shares of Arcturus Therapeutics (NASDAQ:ARCT) saw unusual options activity. After the option alert, the stock price moved up to $43.74.
Mid-Day Market Update: Crude Oil Down 2%; Arcturus Therapeutics Shares Spike Higher
Midway through trading Tuesday, the Dow traded up 0.11% to 34,878.06 while the NASDAQ fell 0.37% to 14,626.97. The S&P also fell, dropping 0.01% to 4,386.68.
48 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures purchased 237,500 shares of Wilhelmina.
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)
Arcturus Announces Approval Of Singapore Clinical Trial Application To Advance ARCT-154 And ARCT-165, Next Generation STARR mRNA Vaccines Targeting SARS-CoV-2 Variants Of Concern, In A Phase 1/2 Study
Singapore is the second country to approve the advancement of ARCT-154 into clinical development
ARCT-154 and ARCT-165 elicit high levels of neutralizing antibodies in non-human primates against multiple variants of
Arcturus Therapeutics Stock Jumps On Establishment Of COVID-19 Vaccine Plant In Vietnam
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) has collaborated with Vinbiocare to establish a manufacturing facility in Vietnam for its investigational COVID-19 vaccines for sale…
Arcturus Therapeutics Collaborates With Vingroup To Establish Manufacturing Facility In Vietnam For Arcturus’ Investigational mRNA Vaccines For COVID-19; Co. To Receive $40M Upfront Payment And Potential Royalties Based On Vaccines Produced
Arcturus will receive $40 million upfront payment and potential royalties based on vaccines produced
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading